C Kollmannsberger1, F Honecker, C Bokemeyer. 1. British Columbia Cancer Agency/University of British Columbia-Vancouver Cancer Centre, Division of Medical Oncology, 600 West 10th Avenue, Vancouver, BC V5Z4E6, Canada. ckollmannsberger@bccancer.bc.ca
Abstract
BACKGROUND: Patients with metastatic testicular cancer exhibit an excellent prognosis. However, the outcome for patients with relapse after cisplatin-based chemotherapy remains unsatisfactory. Several larger studies have been recently published. OBJECTIVE: To review the treatment of patients with testicular cancer after failure of first-line chemotherapy. METHODS: A literature search was performed for studies investigating therapies for relapsed testicular cancer. RESULTS/ CONCLUSIONS: The prognosis of patients relapsing after first-line cisplatin-based chemotherapy has improved with multimodality therapy, including conventional and high-dose chemotherapy, surgery and radiation. Prognostic factors are increasingly used to guide treatment intensity. High-dose chemotherapy has become an accepted treatment option, in particular in patients with poor risk factors at relapse. The outcome of patients with multiply relapsed or cisplatin-refractory disease remains particularly poor. Treatment of relapsed patients requires a close cooperation of medical oncologists, urologists, surgeons and radiation oncologists with extensive experience in this disease.
BACKGROUND:Patients with metastatic testicular cancer exhibit an excellent prognosis. However, the outcome for patients with relapse after cisplatin-based chemotherapy remains unsatisfactory. Several larger studies have been recently published. OBJECTIVE: To review the treatment of patients with testicular cancer after failure of first-line chemotherapy. METHODS: A literature search was performed for studies investigating therapies for relapsed testicular cancer. RESULTS/ CONCLUSIONS: The prognosis of patients relapsing after first-line cisplatin-based chemotherapy has improved with multimodality therapy, including conventional and high-dose chemotherapy, surgery and radiation. Prognostic factors are increasingly used to guide treatment intensity. High-dose chemotherapy has become an accepted treatment option, in particular in patients with poor risk factors at relapse. The outcome of patients with multiply relapsed or cisplatin-refractory disease remains particularly poor. Treatment of relapsed patients requires a close cooperation of medical oncologists, urologists, surgeons and radiation oncologists with extensive experience in this disease.
Authors: Christoph Oing; Anja Lorch; Carsten Bokemeyer; Friedemann Honecker; Jörg Beyer; Lars Arne Berger; Karin Oechsle Journal: J Cancer Res Clin Oncol Date: 2014-11-14 Impact factor: 4.553
Authors: Lars Arne Berger; Carsten Bokemeyer; Anja Lorch; Marcus Hentrich; Hans-Georg Kopp; Thomas Christoph Gauler; Jörg Beyer; Maike de Wit; Frank Mayer; Ina Boehlke; Christoph Oing; Friedemann Honecker; Karin Oechsle Journal: J Cancer Res Clin Oncol Date: 2014-04-03 Impact factor: 4.553
Authors: Christoph Oing; Winfried H Alsdorf; Gunhild von Amsberg; Karin Oechsle; Carsten Bokemeyer Journal: World J Urol Date: 2016-07-23 Impact factor: 4.226